Financial Performance - Medtronic reported Q1 FY26 revenue of $8.539 billion, a 6.7% increase compared to Q1 FY25, with organic revenue growth of 4.8%[24] - Adjusted diluted EPS was $1.26, a 2.4% increase year-over-year[24] - The company is raising FY26 EPS guidance and expects high-single digit EPS growth in FY27[15, 58] Segment Performance - Cardiovascular segment revenue reached $3.285 billion, with 7.0% organic growth[21, 40] - Cardiac Ablation Solutions experienced nearly 50% global growth, including over 70% US growth[15, 32, 39] - Neuroscience segment revenue was $2.416 billion, with 3.1% organic growth[21, 45] - Medical Surgical segment revenue totaled $2.083 billion, with 2.4% organic growth[21, 50] - Diabetes segment revenue was $721 million, with 7.9% organic growth[21, 55] Strategic Initiatives - Medtronic is executing strategic portfolio management, including Diabetes separation within 15 months[15, 55] - The company anticipates a net FY26 tariff impact of approximately $185 million, a decrease from the previous estimate of $200-350 million[15] Future Outlook - Medtronic expects revenue growth to accelerate in the second half of the fiscal year due to significant product launches[14, 31] - Cardiac Ablation Solutions is expected to grow even faster in Q2 and H2 due to PFA supply expansion[15]

June 18, 2025 05:02 PM GMT Medical Technology | North America Off the Beaten Path In this note we flag each week a handful of news drops that we think may have been missed / piqued our interest. [EW, MDT] Real-World Data in EMEA Favoring SAVR vs. TAVR In Younger Patients: A new study in Italy suggests that SAVR may be associated with more favorable mortality outcomes in intermediate surgical risk patients than TAVR, with curves decently below from about 1 year onwards (see below), which in theory is negativ ...

Summary of Edwards Lifesciences (EW) Conference Call Company Overview - **Company**: Edwards Lifesciences (EW) - **Industry**: Medical Devices, specifically focusing on heart valve technologies and related innovations Key Points and Arguments Financial Performance and Guidance - **Q4 and Q1 Performance**: Strong performance in Q4 and Q1, maintaining guidance for 2025 with revenue growth expected between 8% to 10% and EPS between $2.4 to $2.5 [5][11] - **Long-term Growth Commitment**: Aiming for double-digit growth (10%+) starting in 2026, with EPS growth expected to outpace revenue growth [11][12] Product Innovations and Market Opportunities - **TAVR (Transcatheter Aortic Valve Replacement)**: Early approval for TAVR expected to drive multi-year growth opportunities; significant patient benefits anticipated from new technologies [6][30] - **EVOQUE Technology**: CE Mark approval for the first transcatheter mitral replacement in Europe; strong data presented on Resilia technology [6][7] - **Emerging Opportunities**: Acquisition of Jesse Medical and ongoing pivotal studies in heart failure technologies [7][8] Supply Chain and Tariff Impact - **Supply Chain Resilience**: Global supply chain footprint is robust, with minimal impact from tariffs; the company is well-protected against tariff fluctuations [13][14][16] - **Tariff Impact on EPS**: Estimated impact of tariffs on EPS is around $0.05 per share, with more significant effects expected in 2026 [15] NCD (National Coverage Determination) and Regulatory Environment - **NCD Reopening for TAVR**: Anticipation that CMS will reopen the NCD for TAVR based on solid data and the procedure's established status as standard care [25][26] - **Guideline Changes**: Ongoing policy and guideline changes expected to further support TAVR growth [30][39] Training and Market Penetration - **Training for EVOQUE Centers**: Significant demand for EVOQUE centers; training processes in place to ensure rapid onboarding of new centers [51][55] - **Market Awareness**: Efforts underway to educate physicians on new data and implications for practice, aiming to drive referrals to interventionalists [34][40] Acquisitions and Future Growth - **Strategic Acquisitions**: Recent acquisitions (Endotronic, InnoValve, Jesse Medical) are expected to enhance the company's portfolio and address various heart conditions [61][63] - **Long-term Vision**: Commitment to long-term growth in structural heart disease, with expectations for significant contributions from new technologies [50][62] Additional Important Insights - **Leadership and Execution**: Strong leadership team noted for effective management of financial performance and strategic priorities [20][22] - **Patient-Centric Approach**: Emphasis on patient care and outcomes as a core value of the company, beyond just business metrics [37][59] This summary encapsulates the key discussions and insights from the Edwards Lifesciences conference call, highlighting the company's financial outlook, product innovations, market strategies, and commitment to patient care.